U.S. flag

An official website of the United States government

Display Settings:


Send to:

Choose Destination
Accession: PRJEB7339 ID: 261890

Chromosomal Instability in Cell-free DNA Is a Serum Biomarker for Prostate Cancer

DNA was extracted from serum of 204 patients with prostate cancer (Gleason 2 to 10), 207 male controls, benign hyperplasia (n=10) and prostatitis (n=10). DNA was amplified using random primers, tagged with molecular identifiers, sequenced on a SOLiD system and aligned to the human genome. The number of sequence reads of cfDNA was evaluated in sliding 100 kbp intervals for variation from controls. Chromosomal regions with significant variations in alignment hits were used for their ability to segregate patients and matched controls. Using ROC curves to assess diagnostic performance, the number of regions in a first subset (n=177), with variations in alignment hits alone evaluated, provided an AUC of 0.81 (0.7 – 0.9, p<0.001). Using five rounds of 10-fold cross-validation with the full dataset, a final model was established that discriminated prostate cancer from controls with an AUC of 0.92 (0.87 – 0.95), reaching a diagnostic accuracy of 83%. Both benign prostatic hypertrophy and prostatitis could be distinguished from prostate cancer using cfDNA with an accuracy of 90%. Assessment of a limited number of chromosomal structural instabilities using massive parallel sequencing of cfDNA was sufficient to distinguish between prostate cancer and controls. This large cohort demonstrates the utility of cfDNA in prostate cancer recently established in other malignant neoplasms.
SubmissionRegistration date: 24-Sep-2014
Chronix Biomedical GmbH
Project Data:
Resource NameNumber
of Links
Sequence data
SRA Experiments431
Other datasets
SRA Data Details
Data volume, Gbases53
Data volume, Mbytes29463

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center